| Dr Karla Munoz, MD | |
|
27511 Interstate 10 W Bldg 2, Boerne, TX 78006-6513 | |
| (210) 698-0500 | |
| (210) 525-1669 |
| Full Name | Dr Karla Munoz |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 18 Years |
| Location | 27511 Interstate 10 W Bldg 2, Boerne, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740324862 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 254912 (New York) | Secondary |
| 207N00000X | Dermatology | A101267 (California) | Secondary |
| 207N00000X | Dermatology | P4986 (Texas) | Primary |
| Entity Name | Karla N Munoz Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952878944 PECOS PAC ID: 0648519298 Enrollment ID: O20190227000459 |
News Archive
The holidays have come and gone, but many of us may still be battling intense sweet cravings leftover from the season's festivities. Excessive sugar cravings can be a sign that your blood glucose levels are out of balance which, if left unchecked, can lead to insulin resistance and Metabolic Syndrome, also known as "Pre-Diabetes."
Origin Agritech Limited, a technology focused supplier of crop seeds in China, today announced unaudited financial results for the third quarter ended June 30, 2010. Origin prepares its financial statements in accordance with generally accepted accounting principles (GAAP) of the United States.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended June 30, 2010 (2Q10) of $2.00, above management's guidance of $1.65 to $1.70. The 2Q10 results compared to EPS of $1.67 for the quarter ended June 30, 2009 (2Q09). For the six months ended June 30, 2010 (1H10) the company reported $3.52 in EPS compared to $2.89 for the six months ended June 30, 2009 (1H09).
Cellectricon AB and Censo Biotechnologies Ltdare announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research.
Approximately 25% of patients with immune thrombocytopenia purpura who receive treatment with rituximab maintain a treatment-free response lasting for at least 5 years, study findings suggest.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Karla Munoz, MD 27511 Interstate 10 W Bldg 2, Boerne, TX 78006-6513 Ph: (210) 698-0500 | Dr Karla Munoz, MD 27511 Interstate 10 W Bldg 2, Boerne, TX 78006-6513 Ph: (210) 698-0500 |
News Archive
The holidays have come and gone, but many of us may still be battling intense sweet cravings leftover from the season's festivities. Excessive sugar cravings can be a sign that your blood glucose levels are out of balance which, if left unchecked, can lead to insulin resistance and Metabolic Syndrome, also known as "Pre-Diabetes."
Origin Agritech Limited, a technology focused supplier of crop seeds in China, today announced unaudited financial results for the third quarter ended June 30, 2010. Origin prepares its financial statements in accordance with generally accepted accounting principles (GAAP) of the United States.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended June 30, 2010 (2Q10) of $2.00, above management's guidance of $1.65 to $1.70. The 2Q10 results compared to EPS of $1.67 for the quarter ended June 30, 2009 (2Q09). For the six months ended June 30, 2010 (1H10) the company reported $3.52 in EPS compared to $2.89 for the six months ended June 30, 2009 (1H09).
Cellectricon AB and Censo Biotechnologies Ltdare announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research.
Approximately 25% of patients with immune thrombocytopenia purpura who receive treatment with rituximab maintain a treatment-free response lasting for at least 5 years, study findings suggest.
› Verified 4 days ago
Thushan N Desilva, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 120 Old San Antonio Rd, Boerne, TX 78006 Phone: 830-331-4150 | |
Susan J Mahler, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 109 Falls Ct, Suite 100, Boerne, TX 78006 Phone: 210-495-5771 | |
Melanie Fulton Ruiz, NP Dermatology Medicare: Not Enrolled in Medicare Practice Location: 609 S Main St, Boerne, TX 78006 Phone: 210-687-1110 Fax: 210-697-1118 | |
Yang Xia, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 745 W San Antonio Ave # 100, Boerne, TX 78006 Phone: 830-331-9900 | |
Dr. Michael Sorace, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 745 W San Antonio Ave, Suite 100, Boerne, TX 78006 Phone: 210-236-9372 Fax: 210-251-3237 | |
Monica L Mccrary, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 120 Dietert Ave Bldg 300, Boerne, TX 78006 Phone: 830-971-9151 Fax: 830-626-9101 |